US Patent 7,820,681: Colchicine-Ritonavir Dosing Claims, Scope, Expiration, and Patent Landscape

US Patent 7,820,681 protects a narrow method of adjusting oral colchicine dosing when a patient receives 200 mg per day of ritonavir. The patent does not claim colchicine itself, the treatment of gout generally, or a particular colchicine formulation. Its commercial relevance is concentrated in drug labels and prescribing systems that address colchicine use with ritonavir-containing therapies, including HIV regimens and ritonavir-boosted products.

The patent issued October 26, 2010, from an application filed July 31, 2009. Its stated patent term extends to approximately July 31, 2029, subject to any applicable patent-term adjustment or extension recorded by the USPTO. The claims are method-of-treatment claims assigned to the former URL Pharma business, now associated with Takeda’s Colcrys franchise (U.S. Patent No. 7,820,681, 2010; Takeda Pharmaceutical Company Limited, 2012).

What does US Patent 7,820,681 claim?

The patent has four claims. Claim 1 is the only independent claim and establishes the principal infringement test.

Claim 1 requires five elements

A practicing party must satisfy all of the following limitations:

Claim element	Required scope
Patient condition	The patient requires prophylaxis against gout flares
Active ingredient	Colchicine
Route	Oral administration
Concomitant drug	Ritonavir at 200 mg per day
Dose adjustment	Colchicine is reduced to 25% to 50% of the otherwise appropriate dose

The undiscounted colchicine dose identified by the claim is either 0.6 mg twice daily or 0.6 mg once daily. The adjusted dose is therefore:

Intended colchicine regimen	25% adjustment	50% adjustment
0.6 mg twice daily, 1.2 mg/day	0.3 mg/day	0.6 mg/day
0.6 mg once daily, 0.6 mg/day	0.15 mg/day	0.3 mg/day

The claim describes the adjustment as an “adjusted daily dosage amount.” It does not expressly require a particular tablet strength, brand, dosage form, formulation, manufacturer, or ritonavir product.

What is the core legal limitation?

The core limitation is the combination of:

prophylactic treatment of gout flares;
oral colchicine;
concomitant administration of 200 mg per day of ritonavir; and
a colchicine dose equal to 25% to 50% of the normal intended daily dose.

A colchicine prescription for acute gout treatment would not fall within the literal scope of claim 1 unless it also satisfied the prophylaxis limitation. Likewise, a patient receiving ritonavir at a dosage materially different from 200 mg per day may fall outside the express claim language, although infringement could depend on claim construction, dose equivalence, and the facts of use.

What do dependent claims 2, 3, and 4 add?

Claim 2: toxicity monitoring

Claim 2 requires the method of claim 1 plus “carefully monitoring” the patient for potential toxicity. Because claim 2 incorporates every limitation of claim 1, it is narrower than claim 1.

The monitoring language may include clinical observation, laboratory testing, review of gastrointestinal or neuromuscular symptoms, blood-count monitoring, or other measures directed to colchicine toxicity. The claim does not specify a testing interval, laboratory panel, monitoring protocol, or clinical threshold.

Its commercial value is limited because a claimant would first need to prove the underlying claim 1 dosing regimen. The monitoring step may also create proof issues if the alleged infringer is a prescriber, pharmacy, hospital, or patient rather than the manufacturer of the drug.

Claim 3: 25% of the intended dose

Claim 3 narrows claim 1 to an adjusted dose equal to 25% of the intended daily dosage amount.

The principal covered quantities are:

0.3 mg per day when the intended dose is 1.2 mg per day; and
0.15 mg per day when the intended dose is 0.6 mg per day.

Claim 4: 50% of the intended dose

Claim 4 narrows claim 1 to an adjusted dose equal to 50% of the intended daily dosage amount.

The principal covered quantities are:

0.6 mg per day when the intended dose is 1.2 mg per day; and
0.3 mg per day when the intended dose is 0.6 mg per day.

Claims 3 and 4 may be easier to apply where a label or order specifies a discrete 25% or 50% reduction. Claim 1 is broader within the stated range because it covers any adjustment from 25% through 50%.

What formulations are protected by US Patent 7,820,681?

The patent does not claim a specific formulation. It protects a dosing method involving orally administered colchicine.

Covered products could include:

immediate-release colchicine tablets;
generic colchicine tablets;
brand-name Colcrys;
compounded oral colchicine, if the other claim elements are met; and
another oral colchicine dosage form that delivers the claimed adjusted amount.

The patent does not require a particular tablet strength. A 0.3 mg daily dose could be delivered through a single tablet, tablet splitting, multiple lower-strength units, or another oral administration method, depending on the product and prescribing instructions.

A formulation manufacturer could face method-of-use exposure even if its product composition, manufacturing process, and tablet design were not themselves patented. The principal risk would arise from the product label, promotional materials, dosing instructions, or other conduct that encourages the patented combination.

When does US Patent 7,820,681 lose exclusivity?

The ordinary patent term is expected to end in 2029. The application was filed July 31, 2009, and the patent issued October 26, 2010. On the available filing history, the expected base expiration is approximately July 31, 2029, before any applicable term adjustment (U.S. Patent and Trademark Office, n.d.).

The relevant exclusivity timeline is:

Event	Date
Priority/application filing	July 31, 2009
Patent issuance	October 26, 2010
Colcrys FDA approval	July 29, 2009
Three-year clinical-investigation exclusivity for Colcrys	Approximately through July 2012
Expected base patent expiration	Approximately July 31, 2029

The patent term is separate from FDA exclusivity. FDA marketing exclusivity does not extend the patent term, and expiration of FDA exclusivity does not eliminate an unexpired patent.

The exact enforceable expiration date should be read from the USPTO patent-term data and the FDA Orange Book listing. A patent-term adjustment could move the date later, while an adverse terminal disclaimer or other term restriction could affect the calculation.

What is the Orange Book status of US Patent 7,820,681?

US Patent 7,820,681 has been associated with the Colcrys colchicine product and is treated as a method-of-use patent in the regulatory patent landscape for colchicine. Its practical importance depends on the current Orange Book listing, the listed use code, and whether an ANDA applicant can use a section viii statement or must submit a Paragraph IV certification.

For an ANDA applicant, the potential pathways are:

Regulatory route	Commercial effect
Paragraph III certification	Approval deferred until patent expiration
Paragraph IV certification	Applicant may seek approval before expiration and faces possible patent litigation
Section viii statement	Applicant omits the patented method from its labeling, if FDA accepts the carve-out
No certification required	Possible only if the patent is not listed or no longer requires certification

A method-of-use patent does not automatically block approval of every generic colchicine product. The scope of the listed use code and the proposed generic label are central. If the generic label excludes the ritonavir-associated prophylaxis regimen, the applicant may argue that a section viii carve-out avoids the patented use.

The analysis changes if the FDA-required label still instructs prescribers to reduce colchicine in patients taking ritonavir. A label that directly recommends the patented 25%-to-50% regimen can create inducement risk even when the active ingredient and formulation are unpatented.

How does ritonavir affect the patent’s commercial relevance?

Ritonavir is a potent CYP3A4 and P-glycoprotein inhibitor. Colchicine is substantially affected by those pathways. Concomitant use can increase colchicine exposure and create a risk of serious or fatal toxicity. FDA labeling for colchicine and ritonavir-containing products addresses the interaction through contraindications, dose reductions, or heightened monitoring (U.S. Food and Drug Administration, 2023a; U.S. Food and Drug Administration, 2023b).

The claim specifies 200 mg per day of ritonavir. That amount corresponds to common twice-daily ritonavir-boosted regimens and is also relevant to products using 100 mg of ritonavir twice daily. The claim therefore has potential relevance beyond traditional HIV therapy when ritonavir is used as a pharmacokinetic enhancer.

The claim does not require the ritonavir to be administered as a standalone product. Ritonavir supplied as part of a combination product could satisfy the concomitant-administration element if the total daily ritonavir exposure is 200 mg.

What patent litigation and Paragraph IV risks affect generic colchicine?

Generic colchicine applicants

A generic applicant would evaluate at least three infringement theories:

direct infringement through administration of the generic for the patented use;
induced infringement through labeling or promotional materials; and
contributory infringement through distribution of a product with no substantial noninfringing use, a difficult theory for a broadly useful colchicine product.

The strongest risk arises when the proposed label expressly states that patients receiving ritonavir should receive 25% or 50% of the standard colchicine dose for gout-flare prophylaxis.

A generic applicant may reduce risk by:

omitting the patented prophylaxis instruction;
excluding ritonavir-specific dose adjustment language where FDA permits;
limiting labeling to noninfringing gout indications;
avoiding promotional statements encouraging the claimed combination; and
relying on physician-directed use outside the label only where the facts support a noninfringement position.

A section viii carve-out is not guaranteed. FDA may reject a proposed omission if the information is necessary for safe and effective use of the remaining approved indications.

Paragraph IV litigation posture

A Paragraph IV certification alleges that the patent is invalid, unenforceable, or not infringed. The patent’s narrow claim structure gives an ANDA applicant several potential defenses:

the proposed product is not labeled for gout-flare prophylaxis with ritonavir;
the label does not recommend the claimed dose range;
ritonavir is not administered at 200 mg per day;
the claimed adjustment is absent;
the claims are obvious in view of known colchicine-ritonavir interaction data; or
the claims lack adequate written description or enablement for the claimed dosing range.

The patent holder would likely emphasize that the claims are directed to a specific clinical dosing solution, not merely the discovery that ritonavir increases colchicine exposure.

No reliable conclusion on a current, case-specific Paragraph IV settlement or active district-court proceeding should be drawn solely from the claim text. The relevant litigation record must be matched to the specific ANDA, product, patent listing, and docket.

How strong is the patent estate for Colcrys and colchicine?

The broader colchicine patent estate is materially weaker than the estate for a newly discovered small molecule because colchicine has long been known and the foundational compound claims are not in force. Commercial protection instead depends on:

clinical use patents;
dosing and interaction patents;
formulation claims;
manufacturing claims;
FDA exclusivity; and
regulatory barriers created by labeling.

US Patent 7,820,681 is narrower than a product patent but potentially useful because its key variables are visible in prescribing information. A label-based method patent can be commercially significant when the patented dosing instruction is necessary to use the drug safely with a common concomitant medicine.

Its principal strengths are:

a clearly defined concomitant drug;
a specified ritonavir dose;
a specified therapeutic purpose;
a defined colchicine reduction range; and
dependent claims directed to exact 25% and 50% reductions.

Its principal weaknesses are:

the claim covers a narrow patient population;
the normal colchicine regimens are conventional;
the interaction between ritonavir and colchicine was known or clinically foreseeable;
infringement depends on a treatment method rather than manufacture or sale of colchicine alone; and
a generic applicant may attempt a label carve-out.

The patent is therefore stronger against a label that expressly adopts the claimed dosing regimen than against an unapproved, physician-directed use of a generic product.

How does this patent compare with biosimilar and generic risk?

Colchicine is a small molecule, not a biologic. Biosimilar regulation under the Public Health Service Act is not the applicable pathway. Competitive entry occurs through ANDAs, not biosimilar applications.

The main risks are:

Risk category	Relevance
Product patent risk	Low for the old colchicine molecule
Formulation patent risk	Depends on separately listed claims
Method-of-use risk	Material for the ritonavir dose-adjustment regimen
Manufacturing patent risk	Product- and process-specific
FDA exclusivity risk	Historical significance, but not a long-term barrier
Label carve-out risk	Central to generic strategy
Biosimilar risk	Not applicable

Generic colchicine products can generally compete on the molecule after applicable regulatory and patent barriers are cleared. US Patent 7,820,681 does not independently prevent sale of every colchicine product. It targets a specific clinical use and dosing interaction.

What generic launch scenarios exist after patent expiration?

Three practical scenarios are relevant.

Launch before patent expiration through a carve-out

The generic launches with labeling that omits the patented ritonavir-associated prophylaxis regimen. This approach depends on FDA acceptance and the ability to market the product without promoting the carved-out use.

Launch before patent expiration after Paragraph IV litigation

The generic challenges the patent and prevails, obtains a settlement date, or reaches another resolution with the patent holder. The launch date would depend on the litigation outcome, settlement terms, and any 180-day exclusivity consequences applicable to the first filer.

Launch after patent expiration

The generic includes the full relevant labeling after the patent expires. This is the lowest patent-risk pathway, but it may be commercially delayed if other listed patents, exclusivity provisions, or regulatory issues remain.

What geographic coverage does US Patent 7,820,681 provide?

The patent is a United States patent. It does not create rights in Canada, Europe, Japan, or other jurisdictions. International protection would require corresponding national or regional patents.

A multinational colchicine or ritonavir strategy therefore requires separate review of:

PCT filings and national-phase entries;
European Patent Office records;
Canadian and Japanese patents;
local patent-term calculations;
national product-label requirements; and
local litigation or settlement agreements.

The US patent can affect US sales of colchicine products but does not independently restrict foreign manufacture, importation, or prescribing.

Key Takeaways

US Patent 7,820,681 is a narrow method-of-treatment patent for oral colchicine prophylaxis in patients receiving 200 mg per day of ritonavir.
Claim 1 covers a colchicine dose equal to 25% to 50% of 0.6 mg once daily or 0.6 mg twice daily.
Claim 3 isolates the 25% dose reduction, while claim 4 isolates the 50% reduction.
Claim 2 adds patient monitoring for potential colchicine toxicity.
The patent does not claim colchicine, a tablet formulation, or a manufacturing process.
The expected base expiration date is approximately July 31, 2029.
The main generic threat is a label-based Paragraph IV challenge or section viii carve-out.
Biosimilar risk is irrelevant because colchicine is a small molecule.
The patent is most valuable when FDA labeling expressly instructs clinicians to use the claimed ritonavir-associated dose reduction.
The patent is less effective against generic products whose labels omit the patented prophylaxis method and do not promote the combination.

FAQs

Does US Patent 7,820,681 cover Paxlovid?

It may be relevant to colchicine use with Paxlovid because Paxlovid contains ritonavir, but the patent claims a gout-prophylaxis dosing method rather than Paxlovid itself. Infringement would depend on the prescribed use, ritonavir dose, colchicine dose, and applicable labeling.

Does the patent cover colchicine for acute gout attacks?

Not on the face of claim 1. The claim requires prophylaxis of gout flares. Acute treatment is a distinct therapeutic purpose unless a court construes the claim differently under the facts of a particular case.

Can a generic company sell colchicine before July 2029?

Potentially. A generic may seek approval through a Paragraph IV certification, a section viii carve-out, settlement, or another lawful pathway. The patent does not automatically bar all generic colchicine sales.

Is claim 2 likely to apply to ordinary pharmacy dispensing?

Claim 2 requires careful monitoring for potential toxicity in addition to the claim 1 dosing regimen. Whether a pharmacy, prescriber, manufacturer, or healthcare system directly infringes would depend on the specific conduct and attribution of the claimed steps.

Does the patent protect a 0.3 mg colchicine tablet?

No. The claims protect administering an adjusted daily amount, not a particular tablet strength. A 0.3 mg tablet could be relevant to the method, but the tablet itself is not claimed as a composition or dosage form.

References

Takeda Pharmaceutical Company Limited. (2012, May 1). Takeda completes acquisition of URL Pharma, Inc. Takeda Pharmaceutical Company Limited.
U.S. Food and Drug Administration. (2023a). Colcrys (colchicine) prescribing information. FDA.
U.S. Food and Drug Administration. (2023b). Paxlovid (nirmatrelvir and ritonavir) prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Patent and Trademark Office. (n.d.). Patent Center and patent term adjustment information for U.S. Patent No. 7,820,681. USPTO.
U.S. Patent No. 7,820,681. (2010). Methods of treating gout using colchicine. Issued October 26, 2010.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	COLCRYS	colchicine	TABLET;ORAL	022352-001	Jul 29, 2009		DISCN	Yes	No	7,820,681	⤷ Start Trial				METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 7,820,681

Which drugs does patent 7,820,681 protect, and when does it expire?

Summary for Patent: 7,820,681